News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Alkermes
NEWS
JOBS
IN THE PRESS
NEWS
Drug Development
Alkermes Rockets as Depression Drug Aces Key Late-Stage Trial
October 21, 2016
·
2 min read
Pharm Country
How Alkermes Transformed an Anti-Addiction Drug From a Bust to a Hit
September 28, 2016
·
2 min read
Drug Development
Stock Craters as Alkermes’ Depression Drug Fails in Two Late-Stage Trials
January 21, 2016
·
3 min read
Job Trends
1,075 New Jobs to be Added by 11 Life Science Firms in Massachusetts: Amgen, Alnylam, Biogen Idec, Inc. (North Carolina), GE Healthcare Bio-Sciences, Quest Diagnostics, Alkermes, Baxter Healthcare, Merrimack, Synageva BioPharma, Philips Electronics, SMC
March 19, 2015
·
2 min read
Deals
Alkermes Dumps Georgia Facility, Pain Drug Rights to Recro Pharma in $170 Million+ Deal
March 9, 2015
·
2 min read
BioCapital
2015 Could Be Blockbuster Year for Alkermes plc, Says Citi
December 17, 2014
·
2 min read
Genetown
Alkermes plc CEO’s Take On Building Big, Playing Well With Pharma
April 21, 2014
·
1 min read
Pharm Country
How One Biotech Company, Alkermes plc, Survived A Brush With Death
November 11, 2013
·
1 min read
BioCapital
Exenatide Clinical Data Analysis Shows No Increased Risk Of Cardiovascular Events, Amylin Pharmaceuticals, Inc., Eli Lilly and Company And Alkermes Announce
March 27, 2009
·
1 min read
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Press Releases
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
May 12, 2026
·
18 min read
Press Releases
Alkermes plc Reports First Quarter 2026 Financial Results
May 5, 2026
·
1 min read
Press Releases
Alkermes to Report First Quarter Financial Results on May 5, 2026
April 22, 2026
·
1 min read
Press Releases
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
April 17, 2026
·
10 min read
Press Releases
Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry
April 14, 2026
·
16 min read
Press Releases
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
April 2, 2026
·
6 min read
Press Releases
Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program
March 12, 2026
·
3 min read
Press Releases
Alkermes to Present at the Stifel 2026 Virtual CNS Forum
March 11, 2026
·
1 min read
Press Releases
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026
February 25, 2026
·
1 min read
Press Releases
Alkermes plc Announces CEO Succession Plan
February 25, 2026
·
9 min read
